Press ReleasesBecoming A Cannabis Ecosystem: SynBiotic SE Management Update

Becoming A Cannabis Ecosystem: SynBiotic SE Management Update


GOLDEN days are in store for the cannabis industry in Germany. In the run-up to legalisation, SynBiotic SE, Europe’s largest listed corporate group in the hemp and cannabis sector, is expanding its lead in the market. To this end, CEO Lars Müller’s team is putting his corporate group on track, strengthening synergies and turning the group into an ecosystem.

From cultivation to production to trade: “Uniting so many different areas offers a tremendous opportunity,” explains Lars Müller. “This has been our focus over the last few months. We’re also in the process of expanding our cannabis ecosystem and, in line with our buy-and-build investment strategy, we continue to look for exciting companies. We’re already in communication with other interesting players for a possible takeover.”

CBPlus and Medical Cannabis: Operational Group Projects Bring Revenue

Alongside preparations for the legalization of recreational cannabis, the existing legal market for cannabinoids continues to be SynBiotic SE’s core market. With CBPlus – an alternative CBD extract containing cannabinoids and terpenes not derived from hemp – a product designed for the core market recently reached market maturity and was successfully launched.

Müller comments: “CBPlus is showing itself to be a sales hit after only a short time. The first batches have completely sold out since our sales launch, and we’ve already been able to generate sales in the six-digit range.” In the coming weeks, SynBiotic SE will also launch its own medical cannabis brand Hempamed Rx, to be presented at Expopharm, the leading trade fair for the pharmacy market.

What awaits investors at the annual shareholders’ meeting in Q4 2022

SynBiotic delivers pro-forma sales of 15 million euros for 2021 in the group based on preliminary figures. These and other company details such as consolidated financial statements will be presented by the cannabis corporate group at the annual shareholders’ meeting in the fourth quarter of 2022. “We look forward to finally welcoming our investors face to face and demonstrating to them how we plan to become profitable as of 2023,” concludes CEO Lars Müller.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you